Abstract: The present disclosure describes series pH-activable fluorescent probes based on a single BODIPY scaffold selectively targeting lysosomal, mitochondrial, and nucleus. The divergent cell organelle targeting was achieved by synthesizing pH-activable fluorescent probes with differential fluorescence profiles arising due to the presence of a unique functional group in the scaffold. We discovered that the functional group transformation in the same scaffold influences the localization ability of pH-activable fluorescent probes in cell organelle. The development of pH-activable fluorescent probes that target lysosomes and mitochondria organelles in live and fixed primary mouse microglial cells warrants future use in disease-specific biological models.

Abstract: The present invention generally relates to a composition matter useful for diagnosis and treatment of Alzheimer's disease comprising A-L-F or a pharmaceutically acceptable salt thereof, wherein A is beta-amyloid peptide or a fragment thereof, L is an optional linker and F is a pH-responsive fluorophore, dye, or a therapeutic agent. Composition matters, methods of use as well as a kit for diagnosis and/or treatment of Alzheimer's disease are within the scope of this disclosure.